Fairvalue-Calculator Fairvalue-Calculator
EN DE

10x Genomics, Inc (TXG) Fair Value & Analysis

Healthcare · US · Market cap $4.3B

Price$31.87
Fair Value$30.66
Upside-3.8%
Quality95/100
Evidence: Medium Range $23.00 – $38.33

Analysis

10x Genomics, Inc (TXG) currently trades at $31.87, while our model-based Fair Value estimate is $30.66 — implying the stock looks roughly 3.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addi…

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -37% Pro Medicus Limited (PME) -81% BrightSpring Health Services, Inc (BTSG) -61% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -39% M3, Inc (MTHRY) +48%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.